Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

- PMLiVE

Unions blast ‘negative consequences’ for Sweden of a Pfizer-AZ deal

Say proposed takeover posed an imminent risk to country's life science sector

- PMLiVE

AstraZeneca rejects ‘final offer’ from Pfizer

And US pharma company rules out hostile takeover

- PMLiVE

MPs grill Read over Pfizer’s commitments to UK

CEO faces combative parliamentary hearing over AstraZeneca bid

- PMLiVE

Amgen and AZ’s psoriasis antibody clears phase III trial

Brodalumab meets its targets in the AMAGINE-1 study

- PMLiVE

AZ starts pivotal trials of lung cancer immunotherapy

Moves MEDI4736 into phase III testing for non-small cell lung cancer

- PMLiVE

AZ circles wagons as Pfizer hints at hostile takeover

Aims for annual revenues of $45bn by 2023

- PMLiVE

FDA approves AZ’s fish oil drug

Epanova gets green light to reduce high levels of fat in the blood

- PMLiVE

Pfizer faces opposition to AZ takeover as Q1 figures disappoint

Labour leader Ed Miliband calls for public inquiry into deal

- PMLiVE

Caroline Strachan leaves AstraZeneca

She will join American Express as VP, global business consulting for EMEA

- PMLiVE

UPDATE: AZ rejects improved Pfizer bid

Continues to assert independence as Pfizer appeals to Prime Minister David Cameron

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

- PMLiVE

Following the biologic path

Biosimilar regulations in Canada, the US and Europe all have a degree of uncertainty

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links